Navigation Links
Siemens Receives FDA Approval for the VERSANT 440 Molecular System
Date:2/18/2008

tion, and a Laboratory Information System interface for downloading patient work lists and results.

"At Siemens, we are intently focused on the development of advanced systems and solutions that will help clinical laboratories enhance their diagnostic capabilities and the efficiency of their operations," said David Okrongly, senior vice president, Molecular Diagnostics, Siemens Healthcare Diagnostics. "We are excited by the VERSANT 440 System's ability to advance molecular testing capability and productivity for our customers through optimized automation, system flexibility, and assay performance excellence."

The VERSANT 440 Molecular System uses bDNA technology that simplifies testing by eliminating nucleic acid extraction and reducing the risk of cross-contamination. With a high level of reproducibility, VERSANT HCV 3.0 Assay allows viral load changes to be distinguished accurately, enhancing hepatitis C viral load management. The HCV RNA 3.0 Assay run on the VERSANT 440 demonstrates excellent precision across the entire reporting range and equivalent detection of all HCV RNA genotypes. CE Marked in September of 2006, the VERSANT 440 has been successfully launched throughout Europe, Africa, and parts of Asia and the Americas.

About Siemens Healthcare Diagnostics

Siemens Healthcare Diagnostics Division is the leading clinical diagnostics provider in the world. The company offers health care professionals the broadest range of diagnostic products and services that are used for diagnosing medical conditions, monitoring patient therapy and providing quality health care. Siemens' comprehensive portfolio of solutions and highly responsive service are designed to improve clinical outcomes, streamline workflow and enhance the operational efficiency of clinical laboratories around the world. Visit http://www.siemens.com/diagnostics.

About Siemens Healthcare

Siemens Heal
'/>"/>

SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Siemens Healthcare Kicks Off New Era of Expanded Access to High-Field MRI with First Install of Affordable MAGNETOM ESSENZA
2. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
3. VIDEO from Medialink and Siemens: Doctors Trade in their Stethoscopes for Microphones
4. ...And the Grand Prize Goes to... Lockport Memorial Hospital, Winner of Siemens National Win an MRI Contest
5. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
6. Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions
7. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
8. The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology
9. Siemens Financial Services, Inc. Announces Completion of Credit Facility With Merit Mountainside, LLC
10. Siemens Releases New Version of INVISION to Aid Customers in Streamlining Clinical Workflow and Improving Quality of Care
11. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... Hay House is pleased to announce the official release ... (Paperback; $10.82) written by the highly esteemed Tommy Rosen, leader ... is meant to help readers of all kinds end their ... Recovery 2.0 is not the average self-help book, or a ... for what comes next. For many, Alcoholics Anonymous ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... and the Virgin Mary, Paris Hilton has now turned to ... a 100-count thread . ,The socialite has apparently ... her deal with her prison ordeal. ,According to ... she is psychologically still very weak and is holding on ...
... For the first time, an Indian weather station is ... the impact of climate change and provide weather details ... setting up an Integrated Sensor Suite (ISS), a warning ... weather station, at the Chhota Shigri glacier in Himachal ...
... said they could consider closing down a hospital at the ... left to die on the floor of the emergency room. ... by the Los Angeles County department of Health ... and minorities in South Los Angeles. Predictably it has been ...
... Institute for Health and Clinical Excellence (Nice)s suggestion for ... the NHS .,TWENTY thousand people will be condemned to ... decision is implemented, they contended. , ,Both ... all types of wet age-related macular degeneration (AMD), ...
... slowing down in some African countries due to a series ... Bank report as saying . ,According to the ... Kenya, Zimbabwe and urban areas of Ethiopia, Rwanda, Burundi and ... communities are empowered to help themselves with better delivery of ...
... you a doctor, with expertise in anesthetics and obstetrics? You ... ,You can then make a beeline for Temora, a ... Peter Speirs is offering you half a million dollars. ... person, expectant mothers will have to travel an extra 80 kilometres ...
Cached Medicine News:Health News:Indian Weather Station Near Glacier to Study Global Warming 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 3Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 4Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 2Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 3Health News:Half a Million Dollars Offered for GPs With Expertise in Anesthetics and Obstetrics 2
(Date:10/22/2014)... , Oct. 22, 2014 Provectus Biopharmaceuticals, ... therapies. PV-10, its novel investigational drug for cancer, is ... for systemic side effects. Its oncology focus is on ... has completed phase 2 trials of PV-10 as a ... topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... leading biopharmaceutical company dedicated to the research and development ... disorders, is marking Digestive Disease Week (DDW) 2012 in ... lives of patients with Crohn,s disease. UCB will present ... "DDW is an exciting opportunity for UCB to ...
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: